Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy versus gemcitabine and nab-paclitaxel as first-line treatment for recurrent or metastatic pancreatic ductal adenocarcinoma: a randomized, open-label, multicenter, phase III clinical trial (WGOG-PAN 006/ICSBR-2)

作者
Xin Wang,P C Zhang,Dan Cao,Huanji Xu
出处
期刊:Frontiers in Immunology [Frontiers Media]
卷期号:17: 1817221-1817221
标识
DOI:10.3389/fimmu.2026.1817221
摘要

Background: Pancreatic ductal adenocarcinoma remains a malignancy with a dismal prognosis, characterized by a median overall survival of less than one year in the metastatic setting despite standard-of-care chemotherapy regimens like gemcitabine plus nab-paclitaxel. The PDAC tumor microenvironment is notoriously immunosuppressive, rendering single-agent immune checkpoint inhibitors largely ineffective. Stereotactic Body Radiotherapy has emerged as a potential strategy to induce immunogenic cell death and remodel the TME. Based on promising Phase II data demonstrating a 78.48% 6-month progression-free survival rate with the triplet combination of GnP, Serplulimab and SBRT, this Phase III trial aims to validate the efficacy of this "radio-immuno-chemotherapy" strategy. Methods: This prospective, randomized, open-label, multicenter Phase III study will enroll 198 patients with recurrent or metastatic PDAC who are naive to systemic therapy for advanced disease. Participants will be randomized (1:1) to the Experimental Group receiving Serplulimab (300 mg IV, Q3W) combined with Gemcitabine 1000 mg/m² + nab-Paclitaxel 125 mg/m², Days 1, 8, Q3W and SBRT (33-50 Gy/5 fractions) initiated in Cycle 2, or the Control Group receiving GnP alone. Outcomes: The primary endpoint is Overall Survival. Secondary endpoints include progression-free survival, Objective Response Rate, Disease Control Rate, and safety profiles assessed via NCI-CTCAE v5.0. Exploratory endpoints include cyclic multiplex tissue staining assays to evaluate immune spatial interactions. Discussion: This study addresses the critical unmet need in advanced PDAC by evaluating a mechanistic synergy between cytotoxic debulking, radiation-induced immune priming, and checkpoint blockade. If successful, this regimen could establish a new standard of care.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
qqq发布了新的文献求助10
刚刚
小二郎的应助被WYL采纳,获得10
刚刚
刚刚
Lucia发布了新的文献求助10
刚刚
珍珠发布了新的文献求助30
1秒前
行走的猫完成签到 ,获得积分10
1秒前
科目三的应助被笔落惊风雨采纳,获得10
1秒前
完美世界的应助被youyyuy采纳,获得10
1秒前
1秒前
2秒前
melody发布了新的文献求助10
2秒前
奋斗的珍完成签到,获得积分10
2秒前
小黄发布了新的文献求助150
2秒前
2秒前
ke完成签到,获得积分20
2秒前
杨子墨发布了新的文献求助10
3秒前
秋风的应助被Xxxxxxx采纳,获得10
3秒前
coolru的应助被巨蟹柠檬采纳,获得10
3秒前
Bradley发布了新的文献求助10
4秒前
4秒前
balabla完成签到,获得积分10
4秒前
4秒前
共享精神的应助被lisasasasa采纳,获得10
4秒前
彭于晏的应助被嗷嗷嗷采纳,获得10
5秒前
hfy完成签到,获得积分10
5秒前
易123发布了新的文献求助10
5秒前
燕天与完成签到,获得积分10
6秒前
6秒前
慕青的应助被tang采纳,获得10
6秒前
X_runner发布了新的文献求助10
6秒前
杭世立完成签到,获得积分10
6秒前
向语风发布了新的文献求助10
6秒前
sl发布了新的文献求助10
7秒前
我是老大的应助被迅速的晟睿采纳,获得10
7秒前
LANER完成签到 ,获得积分10
7秒前
银烨完成签到,获得积分10
7秒前
cs完成签到,获得积分10
7秒前
QDU的应助被May采纳,获得10
8秒前
FOB发布了新的文献求助10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180713
求助须知:如何正确求助?哪些是违规求助? 9570752
关于积分的说明 21814119
捐赠科研通 7776960
什么是DOI,文献DOI怎么找? 3433298
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479287